Eupraxia Pharmaceuticals Inc. EPRX
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -18.94%
- 1 year
- -1.29%
5D -1.66 (-20.05%)
- Market cap
- 411.68M
- EPS (ttm)
- -1.07
- Shares out
- 35.62M
- YTD return
- -18.94%
- 1-year return
- -1.29%
- 50-day average
- 3.00
- 200-day average
- 2.78
- Volume
- 736.43K
- Avg volume
- 732.14K
- Open
- 6.31
- Previous close
- 6.21
- Day's range
- 6.09 – 6.57
- 52-week range
- 5.63 – 9.32
- Beta
- 1.23
Key statistics
- Enterprise value
- 92.53M
- Price / book
- 38.15
- Free cash flow
- -14.62M
- Total cash
- 23.32M
- Total debt
- 4.66M
- Return on equity
- -314.41%
Fundamental scorecard
3 of 25 checks passed on EPRX’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend No data
Statements to Sep 30, 2026.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | Rodman & Renshaw | init | — | Buy |
About Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- eupraxiapharma.com
News
HC Wainwright & Co. Maintains Buy on Eupraxia Pharmaceuticals, Raises Price Target to $16
Eupraxia Announces $125M At-The-Market Equity Program; Says No Current Plan To Use ATM Program In Near Term
Eupraxia Pharmaceuticals Q3 EPS $(0.23) Beats $(0.28) Estimate
RBC Capital Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $14
Your note
Sign in to keep a note on EPRX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Scotia Capital Inc. | 3.92% | 1,396,281 | 4.31M | Sep 29, 2024 |
| Royal Bank of Canada | 0.76% | 271,287 | 838.28K | Sep 29, 2024 |
| Bank of Montreal /CAN/ | 0.14% | 49,250 | 152.18K | Sep 29, 2024 |
| Goldman Sachs Group Inc | 0.10% | 34,500 | 106.60K | Sep 29, 2024 |
| UBS Group AG | 0.09% | 33,000 | 101.97K | Sep 29, 2024 |
| 180 Wealth Advisors, LLC | 0.04% | 13,000 | 40.17K | Sep 29, 2024 |
